ALK Abello
ALK upgrades its full-year revenue outlook
ALK upgrades its full-year revenue outlook
Inside information
ALK (ALKB:DC / OMX: ALK B) today announced that the 2025 full-year financial outlook has been upgraded.
- Revenue is now expected to grow by 12-14% in local currencies (previously 9-13% growth).
- The operating profit (EBIT) margin is still expected to improve by 5 percentage points to 25%.
The updated outlook reflects higher-than-expected revenue in Europe in Q2 and an improved outlook for the rest of the year. Q2 was positively influenced by sales of adrenaline autoinjectors and by the momentum for tablets in Europe which is expected to continue in the second half of the year. This momentum is expected to be supported by solid growth in sales of tablets in North America. Moreover, the updated forecast reflects reduced risks associated with market conditions in Europe for the rest of the year. On the basis of the improved revenue outlook, ALK has decided to allocate additional funds to strategic growth investments in the second half-year.
According to preliminary financial results for Q2, total revenue grew by 12% in local currencies to DKK 1,527 million (1,374), while EBIT increased by 41% in local currencies to DKK 375 million (264), equivalent to an EBIT margin of 25%.
ALK will publish its Q2 report on 21 August 2025. A presentation for analysts and investors will take place on the same day at 13.30 CEST.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
This information is information that ALK is obliged to make public pursuant to the EU Market Abuse Regulation.
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S12.8.2025 20:36:02 CEST | Press release
Capital Increase in Genmab as a Result of Employee Warrant Exercise
ThreatLocker Inc12.8.2025 20:05:14 CEST | Press release
ThreatLocker Chosen for 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
Idorsia Pharmaceuticals Ltd12.8.2025 19:00:00 CEST | Press release
TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product”
TOUAX12.8.2025 17:45:00 CEST | Press release
Touax: Effective transfer of TOUAX SCA shares to Euronext Growth® Paris and delisting from the regulated market of Euronext Paris
Vaisala Group12.8.2025 17:30:00 CEST | Press release
Vaisala Corporation: Share Repurchase 12.8.2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom